Avid Bioservices Inc (CDMO)

[cjgaddy]

NCI’s Steven Rosenberg speaking 5-5-17 on “Improving ACT” at an AACR workshop in Bethesda, whose chair is PPHM collaborator, Duke’s Herbert K. Lyerly. I just wonder if Dr. Rosenberg is aware of the Jedd Wolchok Lab study, “PS Targeting Improves ACT, Eliminates Advanced Tumors” presented 4-3-17 at AACR’17?

May3-5 2017: “AACR’s Accelerating Anticancer Agent Dev. & Validation Workshop”, Bethesda
"AAADV is the only workshop held in collaboration with the U.S. FDA designed specifically to help participants understand and negotiate the drug development approval process to get effective cancer treatments to patients more quickly."
https://www.acceleratingworkshop.org/2017/workshop
Workshop Chair: Herbert K. Lyerly, Duke Univ. MC (PPHM Collaborator** – see: http://tinyurl.com/zzryfok )
5-5-17 AAADV Workshop Plenary Session III: “New Developments in Cancer Immunotherapy: Generating Prolonged Anti-Cancer Immunity”
Moderators: Ke Liu, FDA; Jeffrey Weber, New York Univ.
**”Improving Adaptive Cell Therapy (ACT) for Cancer” - Steven Rosenberg, NCI
**”Designing New CARs for Cancer Treatment” - Marcela Maus, MassGen
**”Beyond Checkpoint Inhibitors: New Approaches to Altering the Tumor Environment” - Roy S. Herbst, Yale Univ.
---------
**The Duke/H. Kim Lyerly collab: ex: “Anti-PS + Anti-PD-L1 Leads to Greater Anti-Tumor Responses in TNBC” - latest is 10-22-16/AACR I-O Conf. – see: http://tinyurl.com/zzryfok
---------
Is NCI’s Dr. Steven Rosenberg aware of the MSKCC Jedd Wolchok Lab “PS-Targeting Improves ACT Therapy” study presented 4-3-17 at AACR’17?
...AACR17 MSKCC+PPHM: 4-3-17 #1651, “PSTargeting+Adoptive TCell Transfer (ACT) Eliminates Adv. Tumors w/o Off-Target Toxicities, Melanoma” <=NEW(2nd) Joint MemSloan/PPHM study SEE: http://tinyurl.com/lxlltd6